輻射中毒治療市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、適應症、放射類型、最終用戶、地區和競爭格局分類，2021-2031年

全球輻射中毒療法市場（包括旨在減輕電離輻射（主要來自癌症放射療法）對正常組織造成的損害的藥物和生物製藥）預計將從 2025 年的 25.2 億美元成長到 2031 年的 34.7 億美元，複合年成長率達到 5.48%。

推動這一成長的主要因素是全球癌症負擔的日益加重。這導致需要頻繁接受放射治療和毒性管理的患者群體不斷擴大。隨著醫療服務提供者將患者的生活品質 (QOL) 置於優先地位，對防護性干預措施的需求持續成長。美國癌症協會預測，到 2025 年，美國將新增 2,041,910 例癌症病例，這項預測也印證了上述趨勢。然而，放射防護藥物核准的嚴格監管要求嚴重阻礙了市場擴張。這些藥物的研發需要進行複雜的臨床試驗，以確保其不會降低癌症治療的療效，這導致研發週期漫長且需要大量資金投入，從而阻礙了藥物的快速商業化，並限制了新進入者的數量。

市場促進因素

全球癌症發生率的不斷上升以及由此導致的放射治療的普及是輻射中毒治療市場的主要促進因素。由於患者數量的成長，放射治療的需求激增，因此需要採取有效的干涉措施來控制組織損傷並提高患者的生活品質。這迫使醫療系統減輕諸如粘膜炎和皮膚炎等副作用，從而導致對放射防護藥物的需求增加。世界衛生組織（世衛組織）於2024年2月發布的預測顯示，到2050年，新增癌症病例將超過3500萬例，比2022年成長77%，凸顯了患者群體的快速成長。此外，受地緣政治緊張局勢加劇和國家安全考量的影響，各國政府為核防禦和輻射防禦而進行的戰略儲備，也透過增加對急性輻射症候群（ARS）醫療措施的投資，加速了市場成長。例如，HOPO Therapeutics 於 2024 年 10 月獲得了一份價值 2.26 億美元的契約，用於開發治療放射性重金屬暴露的口服療法；據報道，安進公司於 2024 年從美國政府訂單了一份價值 1.28 億美元的 Nplate 訂單。

市場挑戰

嚴格的放射防護劑核准監管環境嚴重阻礙了輻射中毒治療市場的擴張。監管機構採用嚴格的安全標準，並要求進行廣泛而複雜的臨床試驗，以確保這些藥物不會干擾癌症治療中放射線治療的療效。這要求證明藥物在保護健康組織的同時不會意外地保護癌細胞，而這項技術難題延長了核准流程，並延遲了潛在治療方法的上市。漫長的核准週期給製藥研發公司帶來了沉重的經濟負擔，構成了巨大的准入門檻，尤其對於那些缺乏資金支持長期臨床試驗的中小型生物技術公司而言更是如此。根據美國藥品研究與製造商協會（PhRMA）的報告，預計到2024年，生物製藥行業的研發投資將達到約1030億美元，這清楚地表明了這種巨大的財務壓力限制了新進入者的數量，並減少了推向市場的創新治療方法的總量。

市場趨勢

重塑市場的一大關鍵趨勢是人們對植物來源和天然放射防護劑日益成長的興趣，這主要源於對更安全、毒性更低的傳統合成化合物替代品的需求。研發人員正持續研究染料木素等生物活性化合物，這些化合物具有給藥方便、安全性高的優點，使其適用於臨床和生物防禦領域的預防性應用，從而加速了天然產物從科學研究向工業化生產的轉變。例如，2025年3月，Humanetics公司獲得了美國國防部510萬美元的津貼，用於啟動一項生產合作項目，以推進BIO 300的研發。 BIO 300是一種大豆來源的藥物，用於預防急性輻射症候群。同時，研究重點也明顯轉向輻射暴露後緩解劑，優先研發能夠在輻射暴露後減輕組織損傷的療法。此舉旨在應對意外核能事故帶來的嚴峻挑戰，並控制無法進行預處理的癌症患者的副作用。各公司正積極籌集大量資金，以推動專注於這些緩解策略的臨床研發管線。具體而言，這包括靶向發炎路徑以修復輻射損傷。例如，Soligenix 公司於 2025 年 9 月進行公開募股，籌集了 750 萬美元，用於支持其針對口腔粘膜炎和急性輻射症候群等疾病的生物製藥研發管線。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：輻射中毒治療的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品成分（集落刺激因子、碘化鉀、普魯士藍、二乙烯三胺五乙酸、其他）
  • 適應症（急性輻射症候群、慢性放射綜合症）
  • 輻射類型（電離輻射、非電離輻射）
  • 依最終使用者（醫院/診所、門診中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美輻射中毒治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲輻射中毒治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區輻射中毒治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲輻射中毒治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲輻射中毒治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球輻射中毒治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Amgen Inc.
• Jubilant Pharma Limited
• Tanner Pharma Group
• Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
• Recipharm AB
• Mission Pharmacal Company
• Partner Therapeutics, Inc.
• Novartis AG
• Viatris Inc.
• Coherus Biosciences Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Radiation Toxicity Treatment Market, encompassing pharmaceuticals and biological agents aimed at mitigating damage to healthy tissues from ionizing radiation, predominantly from cancer radiotherapy, is projected to grow from USD 2.52 Billion in 2025 to USD 3.47 Billion by 2031, achieving a 5.48% CAGR. A primary driver for this growth is the escalating global cancer burden, which necessitates frequent radiation therapy and expands the patient pool requiring toxicity management, fostering consistent demand for protective interventions as healthcare providers prioritize patient quality of life; the American Cancer Society's projection of 2,041,910 new cancer cases in the U.S. in 2025 underscores this. However, stringent regulatory requirements for approving radioprotective drugs significantly impede market expansion, as the development of these agents mandates complex clinical trials to ensure they do not reduce cancer treatment efficacy, leading to prolonged timelines and substantial financial investment that restricts rapid commercialization and limits new market entrants.

Market Driver

The escalating global incidence of cancer and the concurrent rise in radiation therapy adoption are the primary drivers for the radiation toxicity treatment market. Increased patient volumes lead to a surge in radiotherapy procedures, necessitating effective interventions to manage collateral tissue damage and enhance patient quality of life, compelling healthcare systems to mitigate side effects like mucositis and dermatitis, thereby fueling demand for radioprotective pharmaceuticals. The World Health Organization's February 2024 projection of over 35 million new cancer cases by 2050-a 77% increase from 2022 levels-highlights this rapidly expanding patient pool. Furthermore, strategic government stockpiling for nuclear and radiological defense, driven by heightened geopolitical tensions and national security preparedness, accelerates market growth through active investment in medical countermeasures for acute radiation syndrome (ARS); examples include HOPO Therapeutics' $226 million contract in October 2024 for oral treatments for radioactive heavy metal exposure and Amgen's reported $128 million in U.S. government orders for Nplate in 2024.

Market Challenge

The stringent regulatory landscape governing the approval of radioprotective drugs significantly impedes the expansion of the radiation toxicity treatment market. Regulatory bodies enforce rigorous safety standards, demanding extensive and complex clinical trials to guarantee these agents do not interfere with the therapeutic efficacy of radiation in cancer treatment. This necessitates demonstrating that products protect healthy tissue without inadvertently shielding tumor cells, a technical hurdle that extends approval processes and delays the commercial availability of potential therapies. These protracted timelines impose substantial financial burdens on pharmaceutical developers, creating a formidable barrier to entry, particularly for smaller biotechnology firms lacking the capital to sustain long-term trials. The biopharmaceutical industry's investment of nearly $103 billion in research and development in 2024, as reported by PhRMA, illustrates this immense financial pressure, which restricts the number of new entrants and reduces the overall volume of innovative treatments reaching the market.

Market Trends

A significant trend reshaping the market is the rising interest in plant-derived and natural radioprotective agents, driven by the demand for safer, low-toxicity alternatives to traditional synthetic compounds. Developers are increasingly investigating bioactive compounds like genistein, which offer ease of administration and favorable safety profiles suitable for prophylactic use in both clinical and biodefense settings, thereby accelerating the transition of natural products from academic research to industrial-scale manufacturing; Humanetics Corporation, for instance, initiated a manufacturing collaboration in March 2025, supported by a $5.1 million Department of Defense grant, to advance BIO 300, a soy-derived agent for preventing acute radiation syndrome. Concurrently, there is a distinct shift towards post-exposure radiomitigator research, prioritizing therapeutics that can limit tissue damage when administered after radiation exposure, addressing a critical gap for unanticipated nuclear incidents and managing oncology patient side effects where pre-treatment is not feasible. Companies are actively securing substantial capital to advance clinical pipelines focused on these mitigation strategies, specifically targeting inflammatory pathways to reverse radiation-induced injury, as evidenced by Soligenix Inc.'s September 2025 public offering which raised $7.5 million to support its biotherapeutic pipeline for conditions like oral mucositis and acute radiation syndrome.

Key Market Players

• Amgen Inc.
• Jubilant Pharma Limited
• Tanner Pharma Group
• Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
• Recipharm AB
• Mission Pharmacal Company
• Partner Therapeutics, Inc.
• Novartis AG
• Viatris Inc.
• Coherus Biosciences Inc

Report Scope

In this report, the Global Radiation Toxicity Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiation Toxicity Treatment Market, By Product

• Colony Stimulating Factors
• Potassium Iodide
• Prussian Blue Diethylenetriamine Pentaacetic Acid
• Others

Radiation Toxicity Treatment Market, By Indication

• Acute Radiation Syndrome
• Chronic Radiation Syndrome

Radiation Toxicity Treatment Market, By Radiation Type

• Ionizing Radiation
• Non-ionizing Radiation

Radiation Toxicity Treatment Market, By End-user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Radiation Toxicity Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiation Toxicity Treatment Market.

Available Customizations:

Global Radiation Toxicity Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiation Toxicity Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue Diethylenetriamine Pentaacetic Acid, Others)
  • 5.2.2. By Indication (Acute Radiation Syndrome, Chronic Radiation Syndrome)
  • 5.2.3. By Radiation Type (Ionizing Radiation, Non-ionizing Radiation)
  • 5.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Radiation Toxicity Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Radiation Type
  • 6.2.4. By End-user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Radiation Toxicity Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Radiation Type
      • 6.3.1.2.4. By End-user
  • 6.3.2. Canada Radiation Toxicity Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Radiation Type
      • 6.3.2.2.4. By End-user
  • 6.3.3. Mexico Radiation Toxicity Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Radiation Type
      • 6.3.3.2.4. By End-user

7. Europe Radiation Toxicity Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By Radiation Type
  • 7.2.4. By End-user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Radiation Toxicity Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Radiation Type
      • 7.3.1.2.4. By End-user
  • 7.3.2. France Radiation Toxicity Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Radiation Type
      • 7.3.2.2.4. By End-user
  • 7.3.3. United Kingdom Radiation Toxicity Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Radiation Type
      • 7.3.3.2.4. By End-user
  • 7.3.4. Italy Radiation Toxicity Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Radiation Type
      • 7.3.4.2.4. By End-user
  • 7.3.5. Spain Radiation Toxicity Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Radiation Type
      • 7.3.5.2.4. By End-user

8. Asia Pacific Radiation Toxicity Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By Radiation Type
  • 8.2.4. By End-user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Radiation Toxicity Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Radiation Type
      • 8.3.1.2.4. By End-user
  • 8.3.2. India Radiation Toxicity Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Radiation Type
      • 8.3.2.2.4. By End-user
  • 8.3.3. Japan Radiation Toxicity Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Radiation Type
      • 8.3.3.2.4. By End-user
  • 8.3.4. South Korea Radiation Toxicity Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Radiation Type
      • 8.3.4.2.4. By End-user
  • 8.3.5. Australia Radiation Toxicity Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Radiation Type
      • 8.3.5.2.4. By End-user

9. Middle East & Africa Radiation Toxicity Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By Radiation Type
  • 9.2.4. By End-user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Radiation Toxicity Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Radiation Type
      • 9.3.1.2.4. By End-user
  • 9.3.2. UAE Radiation Toxicity Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Radiation Type
      • 9.3.2.2.4. By End-user
  • 9.3.3. South Africa Radiation Toxicity Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Radiation Type
      • 9.3.3.2.4. By End-user

10. South America Radiation Toxicity Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By Radiation Type
  • 10.2.4. By End-user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Radiation Toxicity Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Radiation Type
      • 10.3.1.2.4. By End-user
  • 10.3.2. Colombia Radiation Toxicity Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Radiation Type
      • 10.3.2.2.4. By End-user
  • 10.3.3. Argentina Radiation Toxicity Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Radiation Type
      • 10.3.3.2.4. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Radiation Toxicity Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Jubilant Pharma Limited
• 15.3. Tanner Pharma Group
• 15.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
• 15.5. Recipharm AB
• 15.6. Mission Pharmacal Company
• 15.7. Partner Therapeutics, Inc.
• 15.8. Novartis AG
• 15.9. Viatris Inc.
• 15.10. Coherus Biosciences Inc

16. Strategic Recommendations

17. About Us & Disclaimer